Melanoma Journal Articles for September 2017

The Lancet
Correspondence

Primary medical therapy for BRAF^V600E-mutant melanoma brain metastases—is this good enough?

Tim J Kruser, Michael A Vogelbaum
Published: September 2017
DOI: http://dx.doi.org/10.1016/S1470-2045(17)30633-2

The Lancet
Correspondence

Primary medical therapy for BRAF^V600E-mutant melanoma brain metastases—is this good enough? – Authors’ reply

Michael A Davies, Philippe Saiag, Georgina V Long
Published: September 2017
DOI: http://dx.doi.org/10.1016/S1470-2045(17)30640-X

Clinical Cancer Research
Cancer Therapy: Clinical

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)

Lisa H. Butterfield, Fengmin Zhao, Sandra Lee, Ahmad A. Tarhini, Kim A. Margolin, Richard L. White, Michael B. Atkins, Gary I. Cohen, Theresa L. Whiteside, John M. Kirkwood and David H. Lawson
DOI: 10.1158/1078-0432.CCR-16-3016 Published September 2017

Journal of Medical Case Reports

Sclerosing angiomatoid nodular transformation of the spleen mimicking metastasis of melanoma: a case report and review of the literature

Ilhan Demirci, Horst Kinkel, Dirk Antoine, Marc Szynaka, Bernd Klosterhalfen, Susanne Herold, Hermann Janßen

First Online: 03 September 2017
https://link.springer.com/article/10.1186/s13256-017-1400-6

The New England Journal of Medicine

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Jeffrey Weber, M.D., Ph.D., Mario Mandala, M.D., Michele Del Vecchio, M.D., Helen J. Gogas, M.D., Ph.D., Ana M. Arance, M.D., Ph.D., C. Lance Cowey, M.D., Stéphane Dalle, M.D., Ph.D., Michael Schenker, M.D., Vanna Chiarion-Sileni, M.D., Ivan Marquez-Rodas, M.D., Ph.D., Jean-Jacques Grob, M.D., Marcus O. Butler, M.D., Mark R. Middleton, Ph.D., Michele Maio, M.D., Ph.D., Victoria Atkinson, M.B., B.S., Paola Queirolo, M.D., Rene Gonzalez, M.D., Ragini R. Kudchadkar, M.D., Michael Smylie, M.D., Nicolas Meyer, M.D., Laurent Mortier, M.D., Ph.D., Michael B. Atkins, M.D., Georgina V. Long, Ph.D., M.B., B.S., Shailender Bhatia, M.D., Celeste Lebbé, M.D., Ph.D., Piotr Rutkowski, M.D., Ph.D., Kenji Yokota, M.D., Naoya Yamazaki, M.D., Ph.D., Tae M. Kim, M.D., Ph.D., Veerle de Pril, M.Sc., Javier Sabater, Pharm.D., M.Sc., Anila Qureshi, M.D., M.P.H., James Larkin, F.R.C.P., Ph.D., and Paolo A. Ascierto, M.D., for the CheckMate 238 Collaborators*

September 10, 2017DOI: 10.1056/NEJMoa1709030

The New England Journal of Medicine

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

The New England Journal of Medicine

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

Georgina V. Long, M.B., B.S., Ph.D., Axel Hauschild, M.D., Ph.D., Mario Santinami, M.D., Victoria Atkinson, M.D., Mario Mandalà, M.D., Vanna Chiarion-Sileni, M.D., James Larkin, Ph.D., Marta Nyakas, M.D., Caroline Dutriaux, M.D., Andrew Haydon, M.B., B.S., Ph.D., Caroline Robert, M.D., Laurent Mortier, M.D., Ph.D., Jacob Schachter, M.D., Dirk Schadendorf, M.D., Ph.D., Thierry Lesimple, M.D., Ruth Plummer, M.D., Ran Ji, Ph.D., Pingkuan Zhang, M.D., Bijoyesh Mookerjee, M.D., Jeff Legos, Ph.D., Richard Kefford, M.B., B.S., Ph.D., Reinhard Dummer, M.D., and John M. Kirkwood, M.D.
September 10, 2017DOI: 10.1056/NEJMoa1708539

Cancer Immunology, Immunotherapy

Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease

Stefan Diem
Omar Hasan Ali
Christoph J. Ackermann
David Bomze
Viktor H. Koelzer
Wolfram Jochum
Daniel E. Speiser
Kirsten D. Mertz
Lukas Flatz

First Online: 11 September 2017

Cancer Immunology, Immunotherapy

Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model

Sotirios P. Fortis
Louisa G. Mahaira
Eleftheria A. Anastasopoulou
Ioannis F. Voutsas
Sonia A. Perez
Constantin N. BaxevanisEmail author

Original Article
First Online: 04 September 2017

Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence The Rule of 2 vs the Rule of 3

Juliette Delaunay, MD¹; Ludovic Martin, MD, PhD²; Brigitte Bressac- de Paillerets, PharmaD, PhD^3,4; et alGerard Duru, ED⁵; Olivier Ingster, MD⁶; Luc Thomas, MD, PhD^1,7,8
JAMA Dermatol. Published online September 13, 2017. doi:10.1001/jamadermatol.2017.2926

Dove Press

Case report of a KIT-mutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy

Authors Luo C, Shen JY, Ying J, Fang XH, Wang XH, Fu ZX, Liu P
Received 14 July 2017
Accepted for publication 26 August 2017
Published 14 September 2017 Volume 2017:10 Pages 4553—4557
DOI https://doi.org/10.2147/OTT.S146409

Changing Treatment Paradigms for Brain Metastases From Melanoma—Part 2: When and How to Use the New Systemic Agents

Friday, September 15, 2017

Clinical Cancer Research

Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis

Ruben A Bartolomé, Carmen Aizpurua, Marta Jaén, Sofia Torres, Eva Calviño, Juan I Imbaud and J. Ignacio Casal
DOI: 10.1158/1078-0432.CCR-17-1444

BMC Cancer

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study

Bernies van der Hiel
John B.A.G. Haanen
Marcel P.M. Stokkel
Daniel S. Peeper
Connie R. Jimenez
Jos H. Beijnen
Bart A. van de Wiel
Ronald Boellaard
Alfons J.M. van den Eertwegh

Open Access
Study protocol
First Online: 15 September 2017

Cancer Neurology in Clinical Practice pp 541-557

Neurological Complications of Malignant Melanoma

Hamza Malek
Annise Wilson
Jeffrey Raizer

Bagged textural and color features for melanoma skin cancer detection in dermoscopic and standard images

Alfed, Naser and Khelifi, Fouad (2017)
Expert Systems with Applications, 90. pp. 101-110. ISSN 0957-4174 https://doi.org/10.1016/j.eswa.2017.08.010

Cancer Discovery

Exploiting drug addiction mechanisms to select against MAPKi-resistant melanoma

Aayoung Hong, Gatien Moriceau, Lu Sun, Shirley Lomeli, Marco Piva, Robert Damoiseaux, Sheri L. Holmen, Norman E. Sharpless, Willy Hugo and Roger S. Lo
DOI: 10.1158/2159-8290.CD-17-0682

Ophthalmology

Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma

Comparison with Institutional Controls

Presented in part as abstracts: the 2012 and 2015 Annual Meetings of the American Society of Clinical Oncology (June 2012 and June 2015, Chicago, Illinois) and the 2015 Biennial Conference of International Society of Ocular Oncology (June 2015, Paris, France).
Matias E. Valsecchi, MD, MS Marlana Orloff, MD, Rino Sato, MD, Inna Chervoneva, PhD, Carol L. Shields, MD, Jerry A. Shields, MD, Michael J. Mastrangelo, MD, Takami Sato, MD,
Manuscript no. 2017-227.
DOI: http://dx.doi.org/10.1016/j.ophtha.2017.08.017

A rational approach to melanoma follow-up in patients with primary cutaneous melanoma

Dicker, T. J., Kavanagh, G. M., Herd, R. M., Ahmad, T., McLaren, K. M., Chetty, U. and Hunter, J. A. A. (1999) A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. British Journal of Dermatology, 140 2: 249-254. doi:10.1046/j.1365-2133.1999.02657.x

DovePress

Challenging the standard of care in advanced melanoma: focus on pembrolizumab

Authors Abdul-Karim RM, Cowey CL
Received 18 March 2017
Accepted for publication 17 July 2017
Published 25 September 2017 Volume 2017:9 Pages 433—442
DOI https://doi.org/10.2147/CMAR.S92546

Cochrane Library

Tests to assist in the staging of cutaneous melanoma: a generic protocol (Protocol)

Dinnes J, Saleh D, Newton-Bishop J, Cheung ST, Nathan P, Matin RN, Chuchu N, Bayliss SE, Takwoingi Y, Davenport C, Godfrey K, O’Sullivan C, Deeks JJ, Williams HC. Tests to assist in the staging of cutaneous melanoma: a generic protocol. Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No.: CD012806. DOI: 10.1002/14651858.CD012806. www.cochranelibrary.com

Science

New insights into melanoma development

Jerry W. Shay

Science 29 Sep 2017:
Vol. 357, Issue 6358, pp. 1358-1359
DOI: 10.1126/science.aao6963

Annals of Translational Medicine

Dendritic cell therapy in melanoma

Authors: Carmen Alvarez-Dominguez, Ricardo Calderón-Gonzalez, Hector Terán-Navarro, David Salcines-Cuevas, Almudena Garcia-Castaño, Javier Freire, Javier Gomez-Roman, Fernando Rivera
Vol 5, No 19 (October 2017)

BioRxiv

A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination

Marco Ranzani, Kristel Kemper, Magali Michaut, Oscar Krijgsman, Nanne Aben, Vivek Iyer, Kim Wong, Theodoros I Roumeliotis, Martin Del Castillo Velasco-Herrera, Jeremie Nsengimana, Gemma Turner, Nicola Thompson, Aida Shahrabi, Marcela Sjoberg, Mamunur Rashid, Anneliese O Speak, Vera Grinkevich, Fiona Behan, David Tamborero, Francesco Iorio, Stijn van Dongen, Graham R Bignell, Clara Alsinet, Sofia Chen, Emmanuelle Supper, Ken Dutton-Regester, Antonia Pritchard, Chi Wong, Anton Enright, Julia Newton-Bishop, Ultan McDermott, Nicholas K Hayward, Jyoti S Choudhary, Kosuke Yusa, Lodewyk Wessels, Mathew J Garnett, Daniel Peeper, David J Adams
doi: https://doi.org/10.1101/195354

Molecular Medicine Reports

MicroRNA?24?1?5p promotes malignant melanoma cell autophagy and apoptosis via regulating ubiquitin D

Yujuan Xiao, Qingchun Diao, Yanhua Liang, Yusheng Peng, Kang Zeng

Published online on: September 26, 2017 https://doi.org/10.3892/mmr.2017.7614

International Journal of Cancer

Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model

Chiara Gabellini ,Elena Gómez-Abenza, Sofia Ibáñez-Molero, Maria G. Tupone, Ana B. Pérez-Oliva, Sofia de Oliveira, Donatella Del Bufalo, Victoriano Mulero,
doi/10.1002/ijc.31075/pdf

NATURE REVIEWS CLINICAL ONCOLOGY | RESEARCH HIGHLIGHT

DRUG THERAPY

Moving on up — from stage IV into stage III

David Killock

Nature Reviews Clinical Oncology (2017)
doi:10.1038/nrclinonc.2017.159
Published online 26 September 2017

Role of poly(?-caprolactone) lipid-core nanocapsules on melanoma–neutrophil crosstalk

Authors Drewes CC, Alves ACS, Hebeda CB, Copetti I, Sandri S, Uchiyama MK, Araki K, Guterres SS, Pohlmann AR, Farsky SH
Received 27 April 2017
Accepted for publication 15 July 2017
Published 27 September 2017 Volume 2017:12 Pages 7153—7163
DOI https://doi.org/10.2147/IJN.S140557

Sentinel Lymph Node Biopsy vs Observation in Thick Melanoma: A Multicenter Propensity Score Matching Study

Aram Boada MD, Antonio Tejera-Vaquerizo MD, Simone Ribero MD, Susana Puig MD, David Moreno-Ramírez MD, Miguel A. Descalzo-Gallego MSc, PhD, María T. Fierro MD, Pietro Quaglino MD, Cristina Carrera MD, Josep Malvehy MD, Sergi Vidal-Sicart MD, Antoni Bennássar MD, Ramón Rull MD, Llucìa Alos MD, Celia Requena MD, Isidro Bolumar MD, Víctor Traves, Ángel Pla MD, María T. Fernández-Figueras MD, Carlos Ferrándiz MD, Iciar Pascual MD, José L. Manzano MD, Marina Sánchez-Lucas MD, Pol Giménez-Xavier PhD, Lara Ferrandiz, Eduardo Nagore MD

Accepted manuscript online: 27 September 2017
DOI: 1002/ijc.31078

Oncology Letters

Melanoma differentiation?associated gene?7 suppresses human gastric cancer cell invasion and migration

Li Xu, Jinyan Chen, Wei Lin, Jinkun Chen, Zhiwei Chen

Published online on: September 27, 2017 https://doi.org/10.3892/ol.2017.7086

Pathology & Oncology Research

Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data

Kata Czirbesz, Eszter Gorka, Tímea Balatoni, Gitta Pánczél, Krisztina Melegh, Péter Kovács, András Gézsi, Gabriella Liszkay

Original Article
First Online: 29 September 2017
Pathol. Oncol. Res. (2017). https://doi.org/10.1007/s12253-017-0324-1

European Journal of Plastic Surgery

Do melanoma patients with melanoma of unknown primary have better survival than patients with melanoma of known primary?

Jes Christian Rødgaard, Ulrik Kjerkegaard, Jens Ahm Sørensen, Lars Bjørn Stolle

Eur J Plast Surg (2017). https://doi.org/10.1007/s00238-017-1363-2

Melanoma Journal Articles for September 2017

Primary medical therapy for BRAF^V600E-mutant melanoma brain metastases—is this good enough?

Primary medical therapy for BRAF^V600E-mutant melanoma brain metastases—is this good enough? – Authors’ reply

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)

Sclerosing angiomatoid nodular transformation of the spleen mimicking metastasis of melanoma: a case report and review of the literature

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease

Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model

Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence The Rule of 2 vs the Rule of 3

Case report of a KIT-mutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy

Changing Treatment Paradigms for Brain Metastases From Melanoma—Part 2: When and How to Use the New Systemic Agents

Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study

Neurological Complications of Malignant Melanoma

Bagged textural and color features for melanoma skin cancer detection in dermoscopic and standard images

Exploiting drug addiction mechanisms to select against MAPKi-resistant melanoma

Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma

Comparison with Institutional Controls

A rational approach to melanoma follow-up in patients with primary cutaneous melanoma

Challenging the standard of care in advanced melanoma: focus on pembrolizumab

Tests to assist in the staging of cutaneous melanoma: a generic protocol (Protocol)

New insights into melanoma development

Annals of Translational Medicine

Dendritic cell therapy in melanoma

A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination

MicroRNA?24?1?5p promotes malignant melanoma cell autophagy and apoptosis via regulating ubiquitin D

Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model

Moving on up — from stage IV into stage III

Role of poly(?-caprolactone) lipid-core nanocapsules on melanoma–neutrophil crosstalk

Sentinel Lymph Node Biopsy vs Observation in Thick Melanoma: A Multicenter Propensity Score Matching Study

Melanoma differentiation?associated gene?7 suppresses human gastric cancer cell invasion and migration

Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data

Do melanoma patients with melanoma of unknown primary have better survival than patients with melanoma of known primary?

Our Partners

Melanoma Research Victoria

Quick Links

Melanoma Journal Articles for September 2017

Primary medical therapy for BRAFV600E-mutant melanoma brain metastases—is this good enough?

Primary medical therapy for BRAFV600E-mutant melanoma brain metastases—is this good enough? – Authors’ reply

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)

Sclerosing angiomatoid nodular transformation of the spleen mimicking metastasis of melanoma: a case report and review of the literature

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease

Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model

Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence The Rule of 2 vs the Rule of 3

Case report of a KIT-mutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy

Changing Treatment Paradigms for Brain Metastases From Melanoma—Part 2: When and How to Use the New Systemic Agents

Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study

Neurological Complications of Malignant Melanoma

Bagged textural and color features for melanoma skin cancer detection in dermoscopic and standard images

Exploiting drug addiction mechanisms to select against MAPKi-resistant melanoma

Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma

Comparison with Institutional Controls

A rational approach to melanoma follow-up in patients with primary cutaneous melanoma

Challenging the standard of care in advanced melanoma: focus on pembrolizumab

Tests to assist in the staging of cutaneous melanoma: a generic protocol (Protocol)

New insights into melanoma development

Annals of Translational Medicine

Dendritic cell therapy in melanoma

A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination

MicroRNA?24?1?5p promotes malignant melanoma cell autophagy and apoptosis via regulating ubiquitin D

Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model

Moving on up — from stage IV into stage III

Role of poly(?-caprolactone) lipid-core nanocapsules on melanoma–neutrophil crosstalk

Sentinel Lymph Node Biopsy vs Observation in Thick Melanoma: A Multicenter Propensity Score Matching Study

Melanoma differentiation?associated gene?7 suppresses human gastric cancer cell invasion and migration

Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data

Do melanoma patients with melanoma of unknown primary have better survival than patients with melanoma of known primary?

Our Partners

Melanoma Research Victoria

Quick Links

Primary medical therapy for BRAF^V600E-mutant melanoma brain metastases—is this good enough?

Primary medical therapy for BRAF^V600E-mutant melanoma brain metastases—is this good enough? – Authors’ reply